Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enveric Biosciences Inc (ENVB)

Enveric Biosciences Inc (ENVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,489
  • Shares Outstanding, K 1,390
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,770 K
  • EBIT $ -10 M
  • EBITDA $ -9 M
  • 60-Month Beta 0.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.28

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7500 +10.86%
on 03/30/26
2.3350 -16.92%
on 03/02/26
-0.4100 (-17.45%)
since 02/27/26
3-Month
1.7500 +10.86%
on 03/30/26
4.6699 -58.46%
on 01/27/26
-2.1700 (-52.80%)
since 12/26/25
52-Week
1.7500 +10.86%
on 03/30/26
17.8404 -89.13%
on 05/13/25
-15.7000 (-89.00%)
since 03/28/25

Most Recent Stories

More News
Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates

Patent provides added depth to Enveric’s EVM301 intellectual property portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions

ENVB : 1.9400 (+8.38%)
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025

Product Development Highlights: Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements...

ENVB : 1.9400 (+8.38%)
Enveric Biosciences Announces Registration of Five Trademarks

Canadian Trademark Office Issues House Marks to Enveric Biosciences, Inc.

ENVB : 1.9400 (+8.38%)
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

ENVB : 1.9400 (+8.38%)
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

Proprietary assays demonstrate dual Gq and β-arrestin signaling at 5-HT₂ A , pathways linked in peer-reviewed studies to antidepressant and anxiolytic effects ...

ENVB : 1.9400 (+8.38%)
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

RCANN ™ Trademark Portfolio Out-Licensed

ENVB : 1.9400 (+8.38%)
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological...

ENVB : 1.9400 (+8.38%)
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological...

ENVB : 1.9400 (+8.38%)
Enveric Biosciences Announces Patent Issuance

U.S. Patent expands the scope of patent protection and increases the number of molecules that Enveric has the potential to develop or license for the treatment of neuropsychiatric conditions.

ENVB : 1.9400 (+8.38%)
ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of...

ENVB : 1.9400 (+8.38%)
FEED : 2.38 (-3.25%)

Business Summary

Enveric Biosciences Inc. is a patient-centric biotechnology company endeavoring to enhance the lives of Cancer Treatments with novel cannabinoid medicines. Enveric Biosciences Inc., formerly known as AMERI Holdings Inc., is based in NAPLES, Fla.

See More

Key Turning Points

3rd Resistance Point 1.9100
2nd Resistance Point 1.8700
1st Resistance Point 1.8300
Last Price 1.9400
1st Support Level 1.7500
2nd Support Level 1.7100
3rd Support Level 1.6700

See More

52-Week High 17.8404
Fibonacci 61.8% 11.6939
Fibonacci 50% 9.7952
Fibonacci 38.2% 7.8965
Last Price 1.9400
52-Week Low 1.7500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.